Trial Profile
Comparison of incidence of major bleeding rates with Rivaroxaban and Warfarin in patients with non valvular atrial fibrillation
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 22 Nov 2016
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Warfarin
- Indications Embolism; Stroke
- Focus Adverse reactions
- 22 Nov 2016 New trial record